JUNE 9, 2015
More than two dozen members of Amgen’s Business Development team will be at the 2015 BIO International Convention held on June 15-18 in Philadelphia, Pennsylvania. Among them will be David Piacquad, Amgen’s senior vice president of Business Development, who will be speaking at two venues.
- Partnering with Amgen Presentation, Tuesday, June 16, 10:15-10:30, Business Forum, Theater 1 “Super Scientist”
Amgen’s head of business development will highlight the important role partnerships have played over Amgen’s 35-years history. He will highlight the highly customized nature of recent deals, note the company’s balanced approach to sourcing innovation, and Amgen’s sharp strategic focus on serious illness in specific therapeutic areas.
- Panel Discussion: “What Are They Doing in There?—The Mysteries and Practices of Large Pharma Transactions Organizations,” Tuesday, June 16, 3:30-4:45, Room 103AB
Piacquad will join industry peers on stage to talk about how Amgen works with potential partners on deals. He’ll highlight how shifts in the industry have changed deal making and the adjustments Amgen has made to better serve its partners.
One-on-One Partnering Meetings
The Business Development team will engage in one-on-one partnering meetings during the convention held in the Business Forum, a great location to build and strengthen relationships.
Additional Amgen Presentations
“The Impact Biosimilars Will Have On States,” Tuesday, June 16, 2:00-3:15
-Kipp Snider, Director, State Government Affairs, Amgen
Panel: “Translational Medicine: Accelerating Successful Pipelines,” Wednesday June 17, 8:00-9:15
-Aarif Khakoo, Site Head, Amgen San Francisco
“Prescriptions for Digital Health—How Tech Will Revolutionize Biopharma and How Not to be Left in the Dust,” Wednesday, June 17, 9:00-10:15
-Kal Patel, Executive Director and Head of Amgen Digital Health
“Achieving Successful Marketing Authorization for Orphan Products: Experiences from Both Sides of the Atlantic,” Wednesday, June 17, 2:00-3:15
-Jim Howley, Executive Director, Global Marketing, Oncology Business Unit, Amgen